
DeepMirror is a drug discovery platform that combines human ingenuity with AI to accelerate the identification of promising drug candidates. Their core product, the DeepMirror App, features a generative molecular AI for molecule design and a predictive engine for molecular properties like potency and ADMET. The platform aims to reduce the time and cost associated with drug discovery, enabling chemists to progress from hit compound to preclinical candidate within months. They emphasize user-friendliness, allowing medicinal chemists of all levels to leverage advanced AI tools. DeepMirror's approach is data-driven, learning from proprietary databases and customer data to provide accurate predictions and build confidence in designed molecules before costly synthesis. They also highlight their commitment to security, offering ISO 27001 certification and end-to-end encryption for user data and intellectual property.

DeepMirror is a drug discovery platform that combines human ingenuity with AI to accelerate the identification of promising drug candidates. Their core product, the DeepMirror App, features a generative molecular AI for molecule design and a predictive engine for molecular properties like potency and ADMET. The platform aims to reduce the time and cost associated with drug discovery, enabling chemists to progress from hit compound to preclinical candidate within months. They emphasize user-friendliness, allowing medicinal chemists of all levels to leverage advanced AI tools. DeepMirror's approach is data-driven, learning from proprietary databases and customer data to provide accurate predictions and build confidence in designed molecules before costly synthesis. They also highlight their commitment to security, offering ISO 27001 certification and end-to-end encryption for user data and intellectual property.
What they do: AI platform for molecule design (generative molecular design + predictive potency and ADMET models)
Founded: 2019 (University of Cambridge origin)
Team size: ~12 employees
Security: ISO 27001 certification and end-to-end encryption (stated)
Recent funding: Pre-Seed round on 2024-07-31; grant funding from Innovate UK
Drug discovery and bioprocess optimisation for pharma, biotech and academic users.
2019
Biotechnology Research
Latest funding event listed as a Pre-Seed round
Innovate UK FASS grant (Transforming Medicines Manufacturing Programme)
Innovate UK Biomedical Catalyst grant
“Innovate UK and bond-st listed among supporters; bond-st appears in recent investor listings”
| Company |
|---|